文献速递痛风与晶体性关节病

Pegloticase治疗慢性难治性痛风:疗效与安全性更新

Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
PubMed 文献 · Semin Arthritis Rheum · 2020-01-01

本文综述了聚乙二醇化尿酸酶(pegloticase)治疗慢性难治性痛风的疗效与安全性。基于两项随机对照试验及开放标签扩展研究,pegloticase可显著降低血尿酸、溶解痛风石、改善关节症状与生活质量,但免疫原性导致抗药抗体产生是主要局限,可通过停药监测及免疫抑制方案管理。

要点

  • Pegloticase通过酶解尿酸降低血尿酸,适用于传统降尿酸药治疗失败的慢性难治性痛风。
  • 研究显示其可溶解痛风石、减少关节肿痛、改善疼痛与生活质量,并显著降低血压。
  • 主要局限为免疫原性及抗药抗体导致清除增加、疗效丧失和输注反应,需监测血尿酸以指导停药。

核心结论

  • Pegloticase可显著降低慢性难治性痛风患者血尿酸、溶解痛风石并改善关节症状与生活质量。
  • 免疫原性所致抗药抗体是主要局限,但可通过停药监测及免疫抑制方案管理。

研究设计与样本

  • 综述基于两项随机对照试验及一项开放标签扩展研究,评估pegloticase治疗慢性难治性痛风的疗效与安全性。

主要发现

  • Pegloticase显著降低血尿酸、溶解痛风石、减少压痛和肿胀关节数、减轻疼痛,并改善患者整体评估与生活质量。
  • Pegloticase显著降低慢性难治性痛风患者血压,但对肾功能无显著影响。
  • 事后分析提示,未达到持续降尿酸的患者仍可从pegloticase治疗中获得显著临床获益。

关键数值与推荐

  • Pegloticase为重组聚乙二醇化哺乳动物尿酸酶,通过酶解尿酸发挥降尿酸作用。

临床怎么用

  • 适用于传统降尿酸药(如别嘌醇、非布司他)治疗未达标的慢性难治性痛风患者。
  • 治疗中需监测血尿酸,出现降尿酸效果丧失时停用pegloticase以避免输注反应。
  • 可采用新给药方案及联用免疫抑制剂以克服免疫原性、扩展获益人群。

局限性

  • 免疫原性及抗药抗体导致药物清除增加、疗效丧失和输注反应是主要局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gout is currently the most frequent cause of inflammatory arthritis worldwide. It results from elevated serum urate and subsequent deposition of monosodium urate crystals in joints and other tissues. While many patients with gout can be managed with conventional agents (e.g., allopurinol, febuxostat), those with chronic refractory gout often fail to achieve treatment goals with these agents. Pegloticase is a recombinant, pegylated mammalian uricase developed for treatment of chronic refractory gout. Pegloticase is different than other urate lowering therapies in that it enzymatically degrades urate. Pegloticase has been evaluated in multiple studies, most importantly in two randomized controlled trials and a follow-up open-label extension. Extensive analysis of results from these studies has shown that pegloticase profoundly lowers serum urate, resolves tophi, reduces tender and swollen joint counts, decreases pain, and improves both patients' global assessments and quality of life. Pegloticase also significantly decreases blood pressure in patients with chronic refractory gout, but has no significant effect on renal function. Post hoc analyses of clinical results also indicated that chronic refractory gout patients not achieving sustained urate lowering still have significant clinical benefits with pegloticase treatment. The major limitation of pegloticase is immunogenicity and the emergence of anti-drug antibodies that result in increased drug clearance, loss of efficacy, and infusion reactions. However, these reactions can be avoided by stopping pegloticase when there is a loss of serum urate lowering. New dosing regimens and co-administration of immunosuppressive agents are also being employed to overcome this limitation and extend the benefits of pegloticase to a larger number of patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020. PMID: 32620200. doi:10.1016/j.semarthrit.2020.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。